It’s Hard for Doctors to Unlearn Things. That’s Costly for All of Us.

It’s Hard for Doctors to Unlearn Things. That’s Costly for All of Us.

  • September 15, 2018
Table of Contents

It’s Hard for Doctors to Unlearn Things. That’s Costly for All of Us.

Procedures live on even after they’ve been proved ineffective. It can lead to harms and wasted resources. Part of a doctor’s tool kit is learning new things, but also unlearning some things.

The second part may be harder than the first. We know it can be hard to persuade physicians to do some things that have proven benefits, such as monitor blood pressure or keep patients on anticoagulants. But it might be even harder to get them to stop doing things.

In May, a systematic review in JAMA Pediatrics looked at the medical literature related to overuse in pediatric care published in 2016. The articles were ranked by the quality of methods; the magnitude of potential harm to patients from overuse; and the potential number of children that might be harmed. In 2016 alone, studies were published that showed that we still recommend that children consume commercial rehydration drinks (like Pedialyte), which cost more, when their drink of choice would do.

We give antidepressants to children too often. We induce deliveries too early, instead of waiting for labor to kick in naturally, which is associated with developmental issues in children born that way. We get X-rays of ankles looking for injuries we almost never find.

And although there’s almost no evidence that hydrolyzed formulas do anything to prevent allergic or autoimmune disease, they’re still recommended in many guidelines.

Source: nytimes.com

Share :
comments powered by Disqus

Related Posts

AI System Approved For Diabetic Retinopathy Diagnosis

AI System Approved For Diabetic Retinopathy Diagnosis

A system designed by a University of Iowa ophthalmologist that uses artificial intelligence (AI) to detect diabetic retinopathy without a person interpreting the results earned Food and Drug Administration (FDA) authorization in April, following a clinical trial in primary care offices. Results of that study were published Aug. 28 online in Nature Digital Medicine, offering the first look at data that led to FDA clearance for IDx-DR, the first medical device that uses AI for the autonomous detection of diabetic retinopathy. The clinical trial, which also was the first study to prospectively assess the safety of an autonomous AI system in patient care, compared the performance of IDx-DR to the gold standard diagnostic for diabetic retinopathy, which is the leading cause of vision loss in adults and one of the most severe complications for the 30.3 million Americans living with diabetes.

Read More
‘Ground-breaking’ diabetes insulin drug trialled in Cardiff

‘Ground-breaking’ diabetes insulin drug trialled in Cardiff

A ‘ground-breaking’ drug that helps people with diabetes re-grow insulin-making cells has been developed. About 19,000 people live with Type 1 of the condition in Wales and 90% have less than 5% of these cells left. This means they have to inject insulin

Read More
UBC breakthrough opens door to $100 ultrasound machine

UBC breakthrough opens door to $100 ultrasound machine

Engineers at the University of British Columbia have developed a new ultrasound transducer, or probe, that could dramatically lower the cost of ultrasound scanners to as little as $100. Their patent-pending innovation—no bigger than a Band-Aid—is portable, wearable and can be powered by a smartphone. Conventional ultrasound scanners use piezoelectric crystals to create images of the inside of the body and send them to a computer to create sonograms.

Read More